The primary objective of this multicenter study is to compare the safety, tolerability and efficacy of sb-204269 w/placebo as add-on therapy in patients with refractory simple or complex paritial seizure (with or without secondarily generalization). another objective is to gather population pharmacokinetic for sb-204269 as adjunct therapy in patients. the patient must have simple (with motor component) or complex partial seizures with or without secondarily generalization.
Showing the most recent 10 out of 565 publications